Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase
The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, especially for large protein biologics.


Pharmaceutical Technology


In time, the structural identity of testicular hyaluronidase was eventually elucidated, albeit through a rather circuitous pathway. The purification to homogeneity of a hyaluronidase from bee venom, and the subsequent amino-acid sequencing and cDNA cloning, revealed significant homology to the cDNA of a recently identified sperm-surface antigen, PH-20 (31, 32). Without any knowledge of its hyaluronidase activity, the PH-20 protein had been previously identified as a glycosyl-phosphatidylinositol (GPI) lipid-anchored antigen on the plasma membrane of sperm. Within this work, expression of PH-20 in rabbit kidney cells showed the hyaluronidase activity associated with the membrane. Biochemical purification and molecular studies have identified a family of hyaluronidase-like genes in the human genome (33). PH-20, however, is the predominant hyaluronidase in mammalian testes, and among the hyaluronidase-like genes, only the PH-20 enzyme is active at neutral pH that degrades GAGs under physiologic conditions. The human enzyme is a 509-amino acid glycoprotein anchored to the plasma membrane through a GPI moiety (34).

An rDNA-derived human PH-20 hyaluronidase enzyme

Hyaluronidase enzymes from testes had been commercially used as "spreading factors" for more than 50 years despite drawbacks and inadequacies. The discovery of the human PH20 gene and its identification as a hyaluronidase, however, unlocked the potential of producing a reliable recombinant human hyaluronidase enzyme.

Molecular engineering and manufacturing. To develop a human PH-20 hyaluronidase, several issues had to be overcome, including the specific identification of the membrane anchor and controversy over whether the soluble human protein retained enzymatic activity at physiologic pH (35, 36).Previous attempts to produce the 382-amino acid bee venom enzyme in bacterial host systems showed only weak activity. Because the human PH20 contained eight additional cysteine residues (12 total) with multiple N-linked glycosylation sites, expression in mammalian systems were considered for deletion mutagenesis (32). Earlier studies showed that deletion mutagenesis of the carboxy terminus of the PH-20 gene near the proposed GPI anchor site or truncated further to the equivalent carboxy terminus of the bee-venom hyaluronidase failed to produce an active enzyme in mammalian cells (35). Therefore, a series of deletion mutants of the PH-20 cDNA were produced containing HIS6 epitope tags at the carboxyl terminus. Soluble hyaluronidase activity was demonstrated in deletion mutants terminating after amino acids 477– 483. In contrast, less than 10% activity was maintained when constructs terminated after amino acid 467 or when using the full-length PH-20 cDNA (37).

The soluble domain of the human PH-20 hyaluronidase cDNA (encoding amino acids 1–482) was cloned into a well-characterized mammalian cell line (Chinese hamster ovary cells) in order to develop a recombinant human hyaluronidase (rHuPH20) for pharmaceutical use. Purified to homogeneity, the rHuPH20 protein is a 61–63 kDa glycosylated enzyme with a specific activity 50–100 fold greater than commercially available animal hyaluronidase extracts (on a unit/mg protein basis) (38). rHuPH20 exists as a homogeneous preparation, in contrast to the multiple impurities in the commercial bovine-derived material. Indeed, only one minor 75 kDa band in the smear of protein cross-reacted strongly with the anti-ram PH-20 monoclonal antibody, confirming that the hyaluronidase enzyme is a minor component of animal-derived extracts, consistent with the low specific activity.

Comparison with bovine-derived material

It was important to compare the spreading activity of rHuPH20 to the original bovine preparations. It was possible that any of the biologically active contaminants in the animal-derived material (including known contaminants such as proteinases, anticoagulants, growth factors, vasopermeability factors, and immunoglobulins) could potentially contribute to the spreading activity (39–43). These non-hyaluronidase impurities, however, did not contribute significantly. The spreading activity from 5 units of rHuPH20 (100,000 USP units/mg protein) was indistinguishable from that of 5 units of a crude commercial bovine hyaluronidase preparation (approximately 700 units/mg protein) on a unit-per-unit basis when calibrated against the HA substrate in vitro.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here